Arcturus Therapeutics

Yahoo Finance • 2 months ago

Meta, Goldman Sachs lead Tuesday's market cap stock movers

Tuesday’s market has seen notable shifts with several stocks making significant intra-day movements. Mega-cap stocks like Facebook Inc (NASDAQ:META) and Goldman Sachs Group (NYSE:GS) are experiencing upward trends, while large-cap stoc... Full story

Yahoo Finance • 2 months ago

Top movers in Tuesday's session

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 2 months ago

Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates

Investing.com - Wells Fargo lowered its price target on Arcturus Therapeutics (NASDAQ:ARCT) to $42.00 from $45.00 on Tuesday while maintaining an Overweight rating on the stock. The biotech company, currently valued at $309 million, has sh... Full story

Yahoo Finance • 2 months ago

Arcturus outlines pivotal trial plans and advances CF and OTC programs with regulatory meetings expected in 2026

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 MANAGEMENT VIEW * CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5-milligram cohort... Full story

Yahoo Finance • 2 months ago

Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates

Investing.com - Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported second quarter EPS of $-0.34, $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $28.3M versus the consensus estimate of $191.77M.... Full story

Yahoo Finance • 2 months ago

Arcturus Therapeutics Q2 2025 Earnings Preview

* Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) is scheduled to announce Q2 earnings results on Monday, August 11th, after market close. * The consensus EPS Estimate is -$0.87 [https://seekingalpha.com/symb... Full story

Yahoo Finance • 2 months ago

Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday

Earnings season continues, with several notable companies set to release their financial results for the upcoming trading day. Leading the pack are mining giant Barrick Gold, biopharmaceutical company Roivant Sciences (NASDAQ:ROIV), and he... Full story

Yahoo Finance • 3 months ago

Arcturus reports positive phase 2 results for OTC deficiency therapy

SAN DIEGO - Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a $375 million market cap biotech company whose stock has seen a -21% return year-to-date, announced positive interim results from Phase 2 trials of ARCT-810, an mRNA therapeut... Full story

Yahoo Finance • 12 months ago

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154,... Full story

Yahoo Finance • 2 years ago

18 High Growth Low PE Stocks

In this article, we will take a detailed look at the18 High Growth Low PE Stocks. For a quick overview of such stocks, read our article 5 High Growth Low PE Stocks. When value stocks came back with a vengeance in 2022, value investors che... Full story

Yahoo Finance • 2 years ago

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare ind... Full story

Yahoo Finance • 2 years ago

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison... Full story

Yahoo Finance • 2 years ago

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of... Full story

Yahoo Finance • 3 years ago

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

KING OF PRUSSIA, Pa., Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arctur... Full story

Yahoo Finance • 3 years ago

Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their strong 147% return over the last three years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For instance the Arcturus Thera... Full story

Yahoo Finance • 3 years ago

CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Three-month data from ARCT-154 booster trial show persistent neutralizing antibody activity against multiple variants of SARS-CoV-2 International pivotal Phase 3 booster trial preparations initiated with global CRO SAN DIEGO, May 05, 202... Full story

Yahoo Finance • 3 years ago

When Will Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Breakeven?

With the business potentially at an important milestone, we thought we'd take a closer look at Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) future prospects. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on... Full story

Yahoo Finance • 4 years ago

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

SAN DIEGO, March 25, 2022--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and... Full story